{'fraction_non_alphanumeric': 0.02561048243001787, 'fraction_numerical': 0.008338296605122097, 'mean_word_length': 5.801619433198381, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolomic profile of aggressive meningiomas by using high-resolution magic angle spinning nuclear magnetic resonance.

Background Meningiomas are in most cases benign brain tumors. The WHO 2016 classification defines three grades of meningioma. This classification had a prognosis value since grade III meningiomas have a worse prognosis value compared to grades I and II. However, some benign or atypical meningiomas can have clinical aggressive behavior. There are currently no reliable markers which allow distinguishing between the meningiomas with a good prognosis and those which may recur. Results We retrospectively analyzed 62 meningioma samples by using high-resolution magic angle spinning (HRMAS) spectrometry (43 metabolites). We described a metabolic profile defined by a high concentration for acetate, threonine, N-acetyl-lysine, hydroxybutyrate, myoinositol, ascorbate, scylloinositol, total choline and a low concentration for aspartate, glucose, isoleucine, valine, adenosine, arginine and alanine. This metabolomics signature was associated with poor prognosis histological markers (Ki-67 ≥ 40%, high histological grade, and negative progesterone receptor expression). We also described a similar metabolomics spectrum between grade III and grade I meningioma. Moreover, all grade I meningioma with low Ki-67 expression and positive progesterone receptor expression did not have the same metabolomics profile. Conclusions The metabolomics analysis could be used to determine an aggressive meningioma in order to discuss a personalized treatment. Further studies are needed to confirm these results and to correlate this metabolic profile with survival data.